Home | Publications | Diseases | Pain place holder
place holder place holder

Pain

The Pain Market Outlook to 2011


Publication Date   June 2006
Publisher   Business Insights
Product Type   Report
Pages   206
ISBN Number   not applicable
Product Code   RBI076
Ask a question about this product?

Price £1,495.00

approximately: $2,640 | €1,896

Summary


The patient populations for neuropathic and nociceptive pain are large, and are driven by separate disease trends that necessitate pain relief; across the seven major markets in 2005 it was estimated that 37.6m individuals suffered from neuropathic pain and 170.1m suffered from nociceptive pain. The major constituents of the neuropathic pain market are lower back pain, neuralgia/fibromyalgia, diabetic neuropathic pain and pain associated with multiple sclerosis. The nociceptive pain market is driven by the prevalence of the major indications of arthritic pain, particularly osteoarthritis and rheumatoid arthritis, post-operative pain, cancer-related pain and HIV-related pain. Current management of pain is mostly pharmacological consisting of the use of opioids, non-opioids and non-steroidal anti-inflammatory drugs (NSAIDs), as well as adjuvant therapies such as anti-depressants and anti-convulsants. Although pain is not a new phenomenon, misdiagnosis and under-treatment continue to prove deleterious to the pain market. Increased education for patients, physicians, nurses and pharmacists is an on-going unmet need that must be addressed. Across the seven major markets, it is forecast that the prevalence of both the neuropathic and nociceptive markets will increase modestly. It is forecast that the prevalence of the neuropathic pain market will increase to 39.1m individuals, which is complimented by the forecast growth of the nociceptive market to include 164.8m individuals in 2011.

Content


  • Executive Summary
    • Patient Potential
    • Global Market Analysis
    • Analysis Of Potential Future Blockbusters
    • Leading Players In The Global Pain Market
  • Chapter 1 Patient Potential
    • Summary
    • Introduction
    • Neuropathic Pain
    • Lower Back Pain
    • Background
    • Diagnosis, Treatment And Management
    • Epidemiology
    • Neuralgia/Fibromyalgia
    • Background
    • Diagnosis, Treatment And Management
    • Epidemiology
    • Diabetic Neuropathic Pain
    • Background
    • Diagnosis, Treatment And Management
    • Epidemiology
    • Pain Associated With Multiple Sclerosis
    • Background
    • Diagnosis, Treatment And Management
    • Epidemiology
    • Nociceptive Pain
    • Arthritic Pain
    • Background
    • Diagnosis, Treatment And Management
    • Epidemiology
    • Post-Operative Pain
    • Background
    • Diagnosis, Treatment And Management
    • Epidemiology
    • Cancer-Related Pain
    • Background
    • Diagnosis, Treatment And Management
    • Epidemiology
    • Hiv Related Pain
    • Background
    • Diagnosis, Treatment And Management
    • Epidemiology
  • Chapter 2 Global Market Analysis
    • Summary
    • Introduction
    • Pain Market Analysis
    • Leading Brands In The Global Pain Market
    • Opioid Market Analysis
    • Leading Brands In The Global Opioid Market
    • Long-Acting Opioid Market Analysis
    • Key Brands Analysis
    • Short-Acting Opioid Market Analysis
    • Key Brands Analysis
    • Class Sales Forecast To 2011
    • Non-Opioid Market Analysis
    • Leading Brands In The Non-Opioid Market
    • Key Brands Analysis
    • Class Sales Forecast To 2011
    • Non-Steroidal Anti-Inflammatory Drugs
    • Leading Brands In The Nsaid Market
    • Key Brands Analysis
    • Class Sales Forecast To 2011
    • Cox-Ii Inhibitor Market Analysis
    • Leading Brands In The Cox-Ii Inhibitor Market
    • Key Brands Analysis
    • Class Sales Forecast To 2011
    • Anti-Convulsants Market Analysis
    • Leading Brands In The Anti-Convulsant Market
    • First-Generation Anti-Convulsants
    • Key Brands Analysis
    • Second-Generation Anti-Convulsants
    • Key Brands Analysis
    • Class Sales Forecast To 2011
    • Global Pain Market Forecasts To 2011
  • Chapter 3 Analysis Of Potential Future
    • Blockbusters
    • Summary
    • Introduction
    • Major Approaches To R&d
    • Leading Drugs In Development
    • Drug Profiles
    • Phase Ii Pipeline Drugs
    • Nw-1029 (Ralfinamide)
    • Phase Iii Pipeline Drugs
    • Tapentadol (Cg5503/R33133)
    • Bicifadine
    • Transacin (Ngx-4010)
    • Neurodex (Dectromorphan/Quinidine)
    • Chronogesic (Sufentanil)
    • Lacosamide
    • M6g (Morphine-6-Glucuronide)
    • Licofelone (Ml3000)
    • Recently Marketed Drugs
    • Lyrica (Pregabalin)
    • Prialt (Ziconotide)
    • Ionsys (Fentanyl Iontophoretic Transdermal System)
    • Depodur (Morphine)
    • Prexige (Lumiracoxib)
    • Forecast Sales Potential
  • Chapter 4 Leading Players In The Global Pain
    • Market
    • Summary
    • Introduction
    • Global Market Shares
    • Pfizer
    • Marketed Products
    • R&d Compounds
    • Pain Portfolio Forecasts To 2011
    • Johnson & Johnson
    • Marketed Products
    • R&d Compounds
    • Pain Portfolio Forecasts To 2011
    • Novartis
    • Marketed Products
    • R&d Compounds
    • Pain Portfolio Forecasts To 2011
    • Glaxosmithkline
    • Marketed Products
    • R&d Compounds
    • Pain Portfolio Forecasts To 2011
    • Mundipharma Int.
    • Marketed Products
    • R&d Compounds
    • Pain Portfolio Forecasts To 2011
    • Abbott
    • Marketed Products
    • R&d Compounds
    • Pain Portfolio Forecasts To 2011
    • Boehringer Ingelheim
    • Marketed Products
    • R&d Compounds
    • Pain Portfolio Forecasts To 2011
    • Sanofi-Aventis
    • Marketed Products
    • R&d Compounds
    • Pain Portfolio Forecasts To 2011
  • Chapter 5 Appendix
    • Ims Sales Data
    • Index
    • Glossary
  • List Of Figures
    • Figure 1.1: Types Of Diabetic Neuropathy
    • Figure 1.2: Types Of Pain In Multiple Sclerosis
    • Figure 1.3: Types Of Nociceptive Cancer-Related Pain
    • Figure 1.4: Sources Of Nociceptive Hiv-Related Pain
    • Figure 2.5: Competitive Dynamics Of The Global Pain Market By Drug Class, 2005
    • Figure 2.6: Competitive Dynamics Of The Leading Products In The Global Pain Market, 2005
    • Figure 2.7: Competitive Dynamics Of The Leading Opioid Products In The Global Pain Market,
    • Figure 2.8: Competitive Dynamics Of The Leading Non-Opioid Products In The Global Pain Market, 2005
    • Figure 2.9: Competitive Dynamics Of The Leading Nsaid Products In The Global Pain Market,
    • Figure 2.10: Competitive Dynamics Of The Leading Cox-Ii Inhibitor Brands In The Global Pain Market, 2005
    • Figure 2.11: Competitive Dynamics Of The Leading Anti-Convulsant Products In The Global Pain Market, 2005
    • Figure 3.12: Leading Recently Launched Products And Late-Stage R&d Compounds Indicated For The Treatment Of Pain, 2006
    • Figure 4.13: Key Players In The Global Pain Market, 2001 And 2005
  • List Of Tables
    • Table 1.1: Estimated Prevalence Of Neuropathic And Nociceptive Pain In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.2: Estimated Prevalence Of Neuropathic Lower Back Pain In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.3: Forecast Prevalence Of Neuropathic Lower Back Pain Across The Seven Major Markets, 2005-11
    • Table 1.4: Estimated Prevalence Of Neuralgia/Fibromyalgia Pain In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.5: Forecast Prevalence Of Neuralgia/Fibromyalgia Across The Seven Major Markets, 2005- 11
    • Table 1.6: Estimated Prevalence Of Diabetic Neuropathic Pain (Dnp) In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.7: Forecast Prevalence Of Diabetic Neuropathic Pain Across The Seven Major Markets, 2005-15
    • Table 1.8: Estimated Prevalence Of Multiple Sclerosis (Ms) In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.9: Forecast Prevalence Of Pain Associated With Multiple Sclerosis Across The Seven Major Markets, 2005-11
    • Table 1.10: Estimated Prevalence Of Oa-Related Pain In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.11: Estimated Prevalence Of Ra Pain In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.12: Forecast Prevalence Of Oa And Ra Related Pain Across The Seven Major Markets, 2005- 11
    • Table 1.13: Estimated Prevalence Of Post-Operative Pain In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.14: Forecast Prevalence Of Post-Operative Pain Across The Seven Major Markets, 2005-11
    • Table 1.15: Estimated Prevalence Of Cancer-Related Pain In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.16: Forecast Prevalence Of Cancer-Related Pain Across The Seven Major Markets, 2005-11
    • Table 1.17: Estimated Prevalence Of Hiv-Related Pain In The Seven Major Pharmaceutical Markets, 2005
    • Table 1.18: Forecast Prevalence Of Hiv-Related Pain Across The Seven Major Markets, 2005-11
    • Table 2.19: Breakdown Of The Global Pain Market By Drug Class, 2001-05
    • Table 2.20: Leading Brands In The Global Pain Market, 2004-05
    • Table 2.21: Leading Brands In The Global Opioid Market, 2004-05
    • Table 2.22: Sales Forecasts For Opioids In The Global Pain Market, 2005-11
    • Table 2.23: Leading Non-Opioid Products In The Global Pain Market, 2004-05
    • Table 2.24: Sales Forecasts For Non-Opioids, 2005-11
    • Table 2.25: Leading Nsaids In The Global Pain Market, 2004-05
    • Table 2.26: Sales Forecasts For Nsaids In The Global Pain Market, 2005-11
    • Table 2.27: Leading Cox-Ii Inhibitor Brands In The Global Pain Market, 2004-05
    • Table 2.28: Sales Forecasts For Cox-Ii Inhibitors, 2005-11
    • Table 2.29: Leading Anti-Convulsant Products In The Global Pain Market, 2004-05
    • Table 2.30: Sales Forecasts For Anti-Convulsants In The Global Pain Market, 2005-11
    • Table 2.31: Sales Forecasts In The Global Pain Market, 2005-11
    • Table 3.32: Sales Forecasts For Key Recently Launched Products And R&d Compounds, 2005-11
    • Table 4.33: Key Players In The Global Pain Market, 2005
    • Table 4.34: Pfizer's Marketed Pain Portfolio, 2005
    • Table 4.35: Pfizer's Pain R&d Pipeline, 2006
    • Table 4.36: Forecast Sales For Pfizer's Pain Portfolio, 2005-11
    • Table 4.37: J&j's Marketed Pain Portfolio, 2005
    • Table 4.38: J&j's Pain R&d Pipeline, 2006
    • Table 4.39: Forecast Sales For J&j's Pain Portfolio, 2005-11
    • Table 4.40: Novartis' Marketed Pain Portfolio, 2005
    • Table 4.41: Novartis' Pain R&d Pipeline, 2006
    • Table 4.42 Forecast Sales For Novartis' Pain Portfolio, 2005-11
    • Table 4.43 Gsk's Marketed Pain Portfolio, 2005
    • Table 4.44: Gsk's Pain R&d Pipeline, 2006
    • Table 4.45: Forecast Sales For Gsk's Pain Portfolio, 2005-11
    • Table 4.46: Mundipharma's Marketed Pain Portfolio, 2005
    • Table 4.47: Forecast Sales For Mundipharma's Pain Portfolio, 2005-11
    • Table 4.48: Abbott's Marketed Pain Portfolio, 2005
    • Table 4.49: Abbott's Pain R&d Pipeline, 2006
    • Table 4.50: Forecast Sales For Abbott's Pain Portfolio, 2005-11
    • Table 4.51: Boehringer Ingelheim's Marketed Pain Portfolio, 2005
    • Table 4.52: Forecast Sales For Boehringer Ingelheim's Pain Portfolio, 2005-11
    • Table 4.53: Sanofi-Aventis' Marketed Pain Portfolio, 2005
    • Table 4.54: Sanofi-Aventis' Pain R&d Pipeline, 2006
    • Table 4.55: Forecast Sales For Sanofi-Aventis' Pain Portfolio, 2005-11